Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
1
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 10051, Taiwan
2
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei 10002, Taiwan
3
National Institute of Environmental Health Sciences, Zhunan 35053, Taiwan
Pharmaceuticals 2022, 15(12), 1538; https://doi.org/10.3390/ph15121538
Submission received: 2 November 2022
/
Revised: 5 December 2022
/
Accepted: 9 December 2022
/
Published: 11 December 2022
(This article belongs to the Special Issue Drug Treatments for Inflammatory Bowel Diseases)
Abstract
:Pioglitazone shows potential benefits in inflammatory bowel disease (IBD) in preclinical studies, but its effect in humans has not been researched. We used a nationwide database of Taiwan’s National Health Insurance to investigate whether pioglitazone might affect IBD risk. We enrolled 12,763 ever users and 12,763 never users matched on a propensity score from patients who had a new diagnosis of type 2 diabetes mellitus between 1999 and 2008. The patients were alive on 1 January 2009, and they were followed up for a new diagnosis of IBD until 31 December 2011. Propensity score-weighted hazard ratios were estimated, and the interactions between pioglitazone and major risk factors of IBD (i.e., psoriasis, arthropathies, dorsopathies, chronic obstructive pulmonary disease/tobacco abuse, and any of the above) and metformin were investigated. At the end of the follow-up, 113 ever users and 139 never users were diagnosed with IBD. When compared to never users, the hazard ratio for ever users was 0.809 (95% confidence interval: 0.631–1.037); and none of the hazard ratios for ever users categorized by tertiles of cumulative duration and cumulative dose reached statistical significance. No interactions with major risk factors or metformin were observed. Our findings suggested a null effect of pioglitazone on IBD.
1. Introduction
Inflammatory bowel disease (IBD), generally classified as Crohn’s disease (CD) and ulcerative colitis (UC) in clinical practice, is characterized by chronic and relapsing colitis due to excessive expression of various inflammatory mediators. Clinical manifestations include watery diarrhea, fatigue, weight loss, abdominal pain, and bleeding, and sometimes it can be life-threatening [1,2]. It is difficult to differentiate between CD and UC from clinical presentations, and laboratory examinations, including colofibroscope, are necessary for more accurate diagnosis [1]. It has been estimated that 10–15% of the population may have some type of colitis [2]. The prevalence of IBD is approximately 0.3% in North America, Oceania, and Europe, and its incidence is either stable or decreasing in these countries. However, since the 1990s, an increased incidence has been observed in newly industrialized countries in Asia, South America, and Africa [3,4]. In Taiwan, the incidence is increasing, and the annual percentage change has been estimated to be 4% to 5% [3].
The etiology of IBD remains to be investigated, but the interplay among the host, microbiota, and environmental factors is important [2,5,6]. More than 230 genetic loci relating to major histocompatibility complex, pattern recognition, inflammation, and apoptosis have been identified [1,7]. However, environmental risk factors relating to industrialization, sanitation, and hygiene are important, and specific risk factors may include metabolic syndrome, lack of exercise, work shift, dietary patterns (less intake of fiber-containing vegetables, fruit, cereal, and nuts, and more intake of calorically dense diet, elaborate meat, high-fat diet, and high-sugar diet), animal protein, milk formula feeding, vitamin D deficiency, excessive sanitation, psychological stress, history of childhood infection and vaccination and use of oral contraceptives, non-steroidal anti-inflammatory drugs and antibiotics [4,7,8]. On the other hand, breastfeeding may provide protection against IBD [4]. Cigarette smoking and appendectomy both seemed to aggravate CD but might alleviate UC [4]. Metabolites derived from gut microbiota play important roles in mediating the hosts’ immune response and release of inflammatory cytokines and, thus, are pivotal in the development of IBD [9].
Thiazolidinedione (TZD) activates the peroxisome proliferator-activator receptor gamma (PPARγ) and improves insulin resistance and has been used for lowering blood glucose in patients with type 2 diabetes mellitus. In in vitro and in vivo preclinical studies, PPARγ activation has been shown to play a role in the regulation of inflammation and immune response in the colon [10], and the role of PPARγ in the treatment of IBD has long been under investigation [2,5,11,12,13,14,15]. Emodin, a Chinese herb-drug used to treat IBD, may act through its activation of PPARγ-related signaling [16]. A recent study showed that the attenuation of IBD by pioglitazone in cellular and animal studies might act through the prevention of cleaving of annexin A1 in macrophages, leading to reduced secretion of inflammatory cytokines [17]. However, evidence of the use of PPARγ agonists in the treatment of human IBD remains to be explored.
To our knowledge, a population-based study investigating the potential role of PPARγ agonists in the development of IBD in humans is still lacking. In the present study, we aimed to investigate the effect of pioglitazone, a PPARγ agonist in the class of TZD, on the risk of IBD in patients with type 2 diabetes mellitus in Taiwan.
2. Results
Table 1 shows the characteristics of never users and ever users in the matched cohort. The two groups were balanced in the distributions of all variables because none of the values of standardized difference was >10%.
Table 2 shows the incidence rates of IBD and the hazard ratios comparing pioglitazone-exposed patients to unexposed patients. The overall hazard ratios and the hazard ratios estimated for each tertile of pioglitazone exposure all favored a null association between pioglitazone use and IBD risk.
3. Discussion
Main Findings
There was a lack of any association between pioglitazone use and IBD (Table 2), and no interaction was observed between pioglitazone and any of the risk factors (Table 3) or pioglitazone and metformin use (Table 4).
- a.
- Discrepancies with preclinical studies
Although PPARγ can play a role in the treatment of IBD through the crosstalk between metabolism and inflammation [5] and preclinical studies favor a potential usefulness of pioglitazone in the treatment of IBD [2,5], such a benefit of pioglitazone could not be observed in humans in this observational study. The discrepancies between preclinical in vitro and in vivo studies and this human observational study require some discussion.
First, animal models of colitis are mainly induced by chemicals such as dextran sodium sulfate, trinitrobenzene sulfonic acid, dinitrobenzene sulfonic acid, oxazolone, and intracolonic instillation of acetic acid [2]. It remains to be explored whether colitis induced by these chemicals can completely mimic human IBD. Furthermore, the administered doses of pioglitazone in in vitro and in vivo studies might be much higher than the available concentrations of pioglitazone derived from the clinical doses used for the treatment of hyperglycemia. In Taiwan, the generally accepted maximum dose of pioglitazone is 30 mg, and we rarely use a dosage of up to 45 mg as has been used in Caucasians [18].
Second, the blood concentration of pioglitazone derived from oral administration does not guarantee a sufficient level of pioglitazone to be delivered to the colon for local activation of PPARγ. Recent drug development for the treatment of IBD focuses on more specific delivery of the drugs by using nanotechnology [19] or topically applied PPARγ agonists [20]. Whether these may improve the efficacy of pioglitazone on IBD prevention or treatment are interesting research topics worthy of investigation.
Third, pioglitazone can target multiple organs and tissues, and activation of PPARγ that acts jointly with retinoid X receptor in different types of cells may result in different biological functions, some even counteracting each other. These may explain the various clinical effects observed for different types of cancer and non-cancer diseases in patients treated with pioglitazone. For example, we did observe an improvement in lipid profiles after pioglitazone treatment in a small clinical trial [21] and a significant risk reduction in dementia [22] and chronic obstructive pulmonary disease [23] in observational studies. However, a potentially higher risk of bladder cancer [24] should be attended to in clinical practice.
However, though not statistically significant, the overall hazard ratio of 0.809 (Table 2) favored an approximately 20% risk reduction in association with pioglitazone use. We could not exclude the possibility of lack of power and the confounding by some unmeasured variables such as microbiota and nutrients.
- b.
- Implications
At least two clinical implications can be derived from the present study. First, findings observed in preclinical studies suggesting potential usefulness in the treatment of IBD by pioglitazone should never be immediately extrapolated to a clinical implication. At least, our present study did not favor such a benefit of pioglitazone.
Second, pioglitazone does not cause hypoglycemia and shows benefits for cardiovascular diseases [18], especially ischemic stroke [25], and is minimally excreted by the kidney [26]. It should be a candidate drug for glucose lowering in patients who fail their treatment by the first-line drug of metformin, especially when the patients have renal insufficiency or are at a high risk of stroke, dementia, and/or chronic obstructive pulmonary disease. However, pioglitazone should better be avoided in patients with a previous diagnosis of bladder cancer or who are at a high risk of developing bladder cancer, such as a positive family history.
- c.
- Strengths
The study has several merits. First, because of the use of a nationwide database of the National Health Insurance (NHI) that has high coverage of >99% of Taiwan’s population, it is reasonable to generalize the findings to the whole population. Second, because we used objective medical records, potential recall bias relating to self-reporting could be avoided. Third, detection biases resulting from different socioeconomic statuses could be minimized because the drug cost-sharing in the NHI is low and can always be waived in veterans, in patients with low income, and in patients who receive prescription refills for chronic disease.
- d.
- Limitations
This study also has some limitations. First, we did not have measurement data of some confounders such as anthropometric factors, lifestyle, physical activity, exposure history to some chemicals, history of childhood infection, stress in life, smoking, alcohol drinking, dietary pattern, nutritional status, micronutrient supplementation, family history, and genetic parameters. Second, we did not have biochemical data such as levels of inflammatory cytokines, glucose, insulin, and lipid profiles. Neither did we have indicators of insulin resistance or β-cell function and gut microbiota information for analyses. Third, the outcome of IBD was defined by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and not by colofibroscopic examinations. Therefore, we could not exclude the potential risk of misdiagnosis in some patients. Because the misclassification was expected to be non-differential, the estimated hazard ratios were supposed to bias toward the null [27,28]. Finally, because the daily dose of pioglitazone used in the Taiwanese and probably also in other Asian populations rarely exceeds 30 mg, whether the clinical use of 45 mg in the Caucasian people [18] would exert a different effect on IBD is an interesting issue that requires additional studies.
4. Materials and Methods
4.1. The National Health Insurance in Taiwan
Taiwan started to implement the so-called NHI on 1 March 1995. The NHI is compulsory and covers >99.6% of Taiwan’s population. The Bureau of NHI signs contracts with all in-hospitals and more than 93% of all medical settings in Taiwan to provide medical care to the insurants. For reimbursement purposes, computerized medical records, including disease diagnoses, medication prescriptions, and performed procedures, have to be submitted to the Bureau of the NHI. The database can be used for academic research after ethics review and approval. The present study was approved (approval number NHIRD-102-175) by the Research Ethics Committee of the National Health Research Institutes. The readers may refer to our previously published paper for a more detailed description of the database [29].
4.2. Enrollment of Study Subjects
Throughout the research period, the ICD-9-CM was used as the disease coding system. Accordingly, diabetes mellitus was coded 250.XX and IBD were coded 555 (regional enteritis) and/or 556 (ulcerative enterocolitis).
We created a cohort consisting of propensity score (PS)-matched pairs of ever users and never users of pioglitazone from the NHI database. Figure 1 shows the stepwise procedures. First, we excluded patients whose diagnosis of diabetes mellitus was made during 1995–1998 and then enrolled 477,207 patients who had a first diagnosis of diabetes mellitus made between 1999 and 2008 with a prescription of antidiabetic drugs for at least two times at outpatient clinics. We then excluded step-by-step the following ineligible patients: (1) patients who died before 1 January 2009 (n = 188), (2) patients who used pioglitazone for the first time after 2009 (n = 58,835), (3) patients who were diagnosed of type 1 diabetes mellitus (n = 2534), (4) patients who had ever been treated with rosiglitazone (n = 51,017), (5) patients who had used pioglitazone for a short period of <180 days (n = 6399), (6) patients who had a diagnosis of IBD before entry or within 6 months of diabetes diagnosis (n = 27,374), and (7) patients who had a short follow-up duration of <180 days (n = 13,692). As a result, we identified an unmatched cohort consisting of 12,763 ever users and 304,405 never users. We then created PS-matched pairs consisting of 12,763 ever users and 12,763 never users (the matched cohort) based on the Greedy 8→1 digit match algorithm. The PS was created by logistic regression from independent variables that included all characteristics listed in Table 1, as described in more detail previously [29].
We deliberately excluded users of rosiglitazone in the analyses for the following reasons. In Taiwan, only rosiglitazone and pioglitazone in the class of TZD have ever been marketed. In addition to their glucose-lowering effects, these two drugs show different safety profiles in several clinical aspects. For example, the meta-analysis published in 2007 that suggested a potential link between rosiglitazone and myocardial infarction and cardiovascular death [30] has led to the withdrawal of rosiglitazone from the markets or the discontinuation of its use in many countries, including Taiwan. On the contrary, clinical trials suggest that pioglitazone significantly improves lipid profiles [21] and reduces cardiovascular diseases in patients with type 2 diabetes mellitus [18] or in patients with ischemic stroke and insulin resistance [25]. Therefore, in the analyses of the safety profile and the risk association with cancer or other non-cancer diseases, pioglitazone and rosiglitazone should be viewed as two different entities.
4.3. Potential Confounders
Potential confounders included in the analyses are listed in Table 1. The occupation was classified as class I (civil servants, teachers, employees of governmental or private businesses, professionals and technicians), class II (people without a specific employer, self-employed people or seamen), class III (farmers or fishermen), and class IV (low-income families supported by social welfare, or veterans). We defined the use of corticosteroids as a consistent use of ≥ 90 days. The ICD-9-CM codes for the disease diagnoses have been reported previously [22].
4.4. Statistical Analyses
We used the SAS statistical software version 9.4 (SAS Institute, Cary, NC, USA), as a tool for analyses being conducted in the matched cohort. p < 0.05 was considered statistically significant.
We calculated the standardized difference for each covariate and defined a value > 10% as an indicator of potential confounding from the variable, which is generally adopted by many investigators [31].
We calculated two parameters for the assessment of a potential dose-response relationship, i.e., the cumulative duration of pioglitazone therapy (expressed in months) and the cumulative dose of pioglitazone therapy (expressed in mg). The incidence density of IBD was calculated with regard to pioglitazone exposure. The numerator of the incidence was the number of new cases of IBD identified during follow-up, and the denominator was the follow-up duration in person-years. We set the follow-up starting date on 1 January 2009 and ended the follow-up on a date no later than 31 December 2011 when whichever of the following events occurred first: a new diagnosis of IBD, death, or the last reimbursement record. We ended follow-up by the end of 2011 because the concern of a potential risk of bladder cancer associated with pioglitazone was raised in that year [24], which might have led to changes in prescription behavior in the attending physicians and nonadherence to the treatment on the side of the patients.
We estimated hazard ratios and their 95% confidence intervals that compared pioglitazone exposure to non-exposure by applying Cox proportional hazards regression incorporated with the inverse probability of treatment weighting using the PS.
Psoriasis, arthropathies, dorsopathies, and chronic obstructive pulmonary disease/tobacco abuse were viewed as potential risk factors for IBD. To evaluate the joint effects of and the interactions between pioglitazone and these risk factors, we estimated hazard ratios in subgroups categorized by the presence and absence of risk factors and pioglitazone, i.e., (1) risk factor (+)/pioglitazone (−) as the referent group; (2) risk factor (+)/pioglitazone (+); (3) risk factor (−)/pioglitazone (−); and (4) risk factor (−)/pioglitazone (+). The value of P-interaction was also estimated for each model.
Metformin use is associated with a reduced risk of IBD in our previous study [32]. Therefore, we also investigated the joint effect of and interaction between metformin and pioglitazone on the risk of IBD.
5. Conclusions
There is a lack of association between pioglitazone use and IBD risk in Taiwanese patients with type 2 diabetes mellitus, and there are no significant interactions between pioglitazone and major risk factors or metformin. Because of the observational design, the potential risk of lack of sufficient power, and the inability to include all potential confounders, further confirmation of our finding is warranted. The daily dose of pioglitazone in Taiwan is generally not more than 30 mg. Whether the use of a higher dose of 45 mg of pioglitazone in Caucasians may exert a clinical benefit on IBD requires further investigation.
Funding
This research was funded by the Ministry of Science and Technology (MOST 103-2314-B-002-187-MY3) of Taiwan.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the National Health Research Institutes (approval number NHIRD-102-175).
Informed Consent Statement
Patient consent was waived because the personal information had been de-identified, and the patient could not be contacted according to local regulations.
Data Availability Statement
Data contained within the article are not readily available because local regulations restrict the public availability of the dataset to protect privacy. Requests to access the datasets should be directed to C.T., ccktsh@ms6.hinet.net.
Acknowledgments
The author wishes to thank Ting-Ting Chan for her excellent performance in the analyses of the data.
Conflicts of Interest
The author declares no conflict of interest.
References
- Flynn, S.; Eisenstein, S. Inflammatory bowel disease presentation and diagnosis. Surg. Clin. N. Am. 2019, 99, 1051–1062. [Google Scholar] [CrossRef] [PubMed]
- Decara, J.; Rivera, P.; López-Gambero, A.J.; Serrano, A.; Pavón, F.J.; Baixeras, E.; Rodríguez de Fonseca, F.; Suárez, J. Peroxisome proliferator-activated receptors: Experimental targeting for the treatment of inflammatory bowel diseases. Front. Pharmacol. 2020, 11, 730. [Google Scholar] [CrossRef] [PubMed]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018, 390, 2769–2778. [Google Scholar] [CrossRef] [PubMed]
- Baumgart, D.C.; Carding, S.R. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007, 369, 1627–1640. [Google Scholar] [CrossRef] [PubMed]
- Caioni, G.; Viscido, A.; d’Angelo, M.; Panella, G.; Castelli, V.; Merola, C.; Frieri, G.; Latella, G.; Cimini, A.; Benedetti, E. Inflammatory bowel disease: New insights into the interplay between environmental factors and PPARγ. Int. J. Mol. Sci. 2021, 22, 985. [Google Scholar] [CrossRef]
- Verdugo-Meza, A.; Ye, J.; Dadlani, H.; Ghosh, S.; Gibson, D.L. Connecting the dots between inflammatory bowel disease and metabolic syndrome: A focus on gut-derived metabolites. Nutrients 2020, 12, 1434. [Google Scholar] [CrossRef]
- Actis, G.C.; Pellicano, R.; Fagoonee, S.; Ribaldone, D.G. History of inflammatory bowel diseases. J. Clin. Med. 2019, 8, 1970. [Google Scholar] [CrossRef] [Green Version]
- Celiberto, L.S.; Graef, F.A.; Healey, G.R.; Bosman, E.S.; Jacobson, K.; Sly, L.M.; Vallance, B.A. Inflammatory bowel disease and immunonutrition: Novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology 2018, 155, 36–52. [Google Scholar] [CrossRef]
- Lavelle, A.; Sokol, H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 223–237. [Google Scholar] [CrossRef]
- Speca, S.; Dubuquoy, L.; Desreumaux, P. Peroxisome proliferator-activated receptor gamma in the colon: Inflammation and innate antimicrobial immunity. J. Clin. Gastroenterol. 2014, 48 (Suppl. 1), S23–S27. [Google Scholar] [CrossRef]
- Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55, 1341–1349. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vetuschi, A.; Pompili, S.; Gaudio, E.; Latella, G.; Sferra, R. PPAR-γ with its anti-inflammatory anti-fibrotic action could be an effective therapeutic target in IBD. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8839–8848. [Google Scholar] [PubMed]
- Venkataraman, B.; Ojha, S.; Belur, P.D.; Bhongade, B.; Raj, V.; Collin, P.D.; Adrian, T.E.; Subramanya, S.B. Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases. Phytother. Res. 2020, 34, 1530–1549. [Google Scholar] [CrossRef] [PubMed]
- Celinski, K.; Dworzanski, T.; Fornal, R.; Korolczuk, A.; Madro, A.; Brzozowski, T.; Slomka, M. Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J. Physiol. Pharmacol. 2013, 64, 587–595. [Google Scholar]
- Fang, J.; Wang, H.; Xue, Z.; Cheng, Y.; Zhang, X. PPARγ: The central mucus barrier coordinator in ulcerative colitis. Inflamm. Bowel Dis. 2021, 27, 732–741. [Google Scholar] [CrossRef]
- Luo, S.; He, J.; Huang, S.; Wang, X.; Su, Y.; Li, Y.; Chen, Y.; Yang, G.; Huang, B.; Guo, S.; et al. Emodin targeting the colonic metabolism via PPARγ alleviates UC by inhibiting facultative anaerobe. Phytomedicine 2022, 104, 154106. [Google Scholar] [CrossRef]
- da Rocha, G.H.O.; de Paula-Silva, M.; Broering, M.F.; Scharf, P.R.D.S.; Matsuyama, L.S.A.S.; Maria-Engler, S.S.; Farsky, S.H.P. Pioglitazone-mediated attenuation of experimental colitis relies on cleaving of annexin A1 released by macrophages. Front. Pharmacol. 2020, 11, 591561. [Google Scholar] [CrossRef]
- Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefèbvre, P.J.; Murray, G.D.; et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005, 366, 1279–1289. [Google Scholar] [CrossRef]
- Sun, T.; Kwong, C.H.T.; Gao, C.; Wei, J.; Yue, L.; Zhang, J.; Ye, R.D.; Wang, R. Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine. Theranostics 2020, 10, 10106–10119. [Google Scholar] [CrossRef]
- Da Silva, S.; Keita, Å.V.; Mohlin, S.; Påhlman, S.; Theodorou, V.; Påhlman, I.; Mattson, J.P.; Söderholm, J.D. A novel topical PPARγ agonist induces PPARγ activity in ulcerative colitis mucosa and prevents and reverses inflammation in induced colitis models. Inflamm. Bowel Dis. 2018, 24, 792–805. [Google Scholar] [CrossRef]
- Tseng, C.H.; Huang, T.S. Pioglitazone with sulfonylurea: Glycemic and lipid effects in Taiwanese diabetic patients. Diabetes Res. Clin. Pract. 2005, 70, 193–194. [Google Scholar] [CrossRef] [PubMed]
- Tseng, C.H. Pioglitazone reduces dementia risk in patients with type 2 diabetes mellitus: A retrospective cohort analysis. J. Clin. Med. 2018, 7, 306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tseng, C.H. Pioglitazone and risk of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus. Int J COPD. 2022, 17, 285–295. [Google Scholar] [CrossRef] [PubMed]
- Lewis, J.D.; Ferrara, A.; Peng, T.; Hedderson, M.; Bilker, W.B.; Quesenberry, C.P., Jr.; Vaughn, D.J.; Nessel, L.; Selby, J.; Strom, B.L. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011, 34, 916–922. [Google Scholar] [CrossRef] [Green Version]
- Kernan, W.N.; Viscoli, C.M.; Furie, K.L.; Young, L.H.; Inzucchi, S.E.; Gorman, M.; Guarino, P.D.; Lovejoy, A.M.; Peduzzi, P.N.; Conwit, R.; et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 2016, 374, 1321–1331. [Google Scholar] [CrossRef]
- Al-Majed, A.; Bakheit, A.H.; Abdel Aziz, H.A.; Alharbi, H.; Al-Jenoobi, F.I. Pioglitazone. Profiles Drug Subst. Excip. Relat. Methodol. 2016, 41, 379–438. [Google Scholar]
- Pearce, N.; Checkoway, H.; Kriebel, D. Bias in occupational epidemiology studies. Occup. Environ. Med. 2007, 64, 562–568. [Google Scholar] [CrossRef] [Green Version]
- Kesmodel, U.S. Information bias in epidemiological studies with a special focus on obstetrics and gynecology. Acta Obstet. Gynecol. Scand. 2018, 97, 417–423. [Google Scholar] [CrossRef] [Green Version]
- Tseng, C.H. Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis. Diabetes Metab. 2017, 43, 438–445. [Google Scholar] [CrossRef]
- Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457–2471. [Google Scholar] [CrossRef] [Green Version]
- Austin, P.C.; Stuart, E.A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 2015, 34, 3661–3679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tseng, C.H. Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus. J. Crohn’s Colitis 2021, 15, 64–73. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Flowchart showing the stepwise procedures followed in the enrollment of propensity score-matched pairs of pioglitazone ever users and never users.
Figure 1.
Flowchart showing the stepwise procedures followed in the enrollment of propensity score-matched pairs of pioglitazone ever users and never users.
Table 1.
Characteristics of pioglitazone never users and ever users.
| Characteristics | Never Users | Ever Users | Standardized Difference | ||
|---|---|---|---|---|---|
| (n = 12,763) | (n = 12,763) | ||||
| n | % | n | % | ||
| Basic data | |||||
| Age * (years) | 61.01 | 12.17 | 60.95 | 11.50 | −0.68 |
| Diabetes duration * (years) | 6.51 | 2.74 | 6.50 | 2.59 | −0.40 |
| Sex (men) | 7219 | 56.56 | 7218 | 56.55 | −0.03 |
| Occupation | |||||
| I | 4966 | 38.91 | 4920 | 38.55 | |
| II | 2814 | 22.05 | 2800 | 21.94 | −0.25 |
| III | 2505 | 19.63 | 2533 | 19.85 | 0.50 |
| IV | 2478 | 19.42 | 2510 | 19.67 | 0.68 |
| Living region | |||||
| Taipei | 5068 | 39.71 | 5097 | 39.94 | |
| Northern | 1326 | 10.39 | 1327 | 10.40 | 0.10 |
| Central | 2044 | 16.02 | 15.69 | −0.84 | |
| Southern | 1574 | 12.33 | 1609 | 12.61 | 0.78 |
| Kao-Ping and Eastern | 2751 | 21.55 | 2727 | 21.37 | −0.48 |
| Major comorbidities associated with diabetes mellitus | |||||
| Hypertension | 10,370 | 81.25 | 10,422 | 81.66 | 0.97 |
| Dyslipidemia | 10,915 | 85.52 | 10,907 | 85.46 | −0.17 |
| Obesity | 715 | 5.60 | 785 | 6.15 | 2.32 |
| Diabetes-related complications | |||||
| Nephropathy | 3290 | 25.78 | 3245 | 25.43 | −0.91 |
| Eye disease | 4302 | 33.71 | 4352 | 34.10 | 0.85 |
| Diabetic polyneuropathy | 3610 | 28.28 | 3617 | 28.34 | 0.08 |
| Stroke | 3113 | 24.39 | 3175 | 24.88 | 1.02 |
| Ischemic heart disease | 5419 | 42.46 | 5479 | 42.93 | 0.84 |
| Peripheral arterial disease | 3116 | 24.41 | 3090 | 24.21 | −0.49 |
| Factors that might affect exposure/outcome | |||||
| Head injury | 436 | 3.42 | 440 | 3.45 | 0.12 |
| Parkinson’s disease | 286 | 2.24 | 272 | 2.13 | −0.81 |
| Hypoglycemia | 473 | 3.71 | 496 | 3.89 | 0.85 |
| Chronic obstructive pulmonary disease | 5759 | 45.12 | 5812 | 45.54 | 0.76 |
| Tobacco abuse | 486 | 3.81 | 504 | 3.95 | 0.65 |
| Alcohol-related diagnoses | 702 | 5.50 | 698 | 5.47 | 0.02 |
| Heart failure | 1932 | 15.14 | 1948 | 15.26 | 0.25 |
| Gingival and periodontal diseases | 11,232 | 88.00 | 11,181 | 87.60 | −1.16 |
| Pneumonia | 1576 | 12.35 | 1595 | 12.50 | 0.29 |
| Pulmonary tuberculosis | 388 | 3.04 | 444 | 3.48 | 2.40 |
| Osteoporosis | 2108 | 16.52 | 2195 | 17.20 | 1.74 |
| Human immunodeficiency virus infection | 12 | 0.09 | 8 | 0.06 | −1.31 |
| Cancer | 1579 | 12.37 | 1657 | 12.98 | 1.80 |
| Dementia | 677 | 5.30 | 653 | 5.12 | −0.99 |
| Valvular heart disease | 1025 | 8.03 | 1043 | 8.17 | 0.51 |
| Arthropathies | 9628 | 75.44 | 9685 | 75.88 | 1.02 |
| Psoriasis | 419 | 3.28 | 374 | 2.93 | −2.19 |
| Dorsopathies | 9777 | 76.60 | 9792 | 76.72 | 0.25 |
| Liver cirrhosis | 360 | 2.82 | 352 | 2.76 | −0.45 |
| Other chronic non-alcoholic liver diseases | 1171 | 9.17 | 1210 | 9.48 | 0.99 |
| Hepatitis B virus infection | 452 | 3.54 | 465 | 3.64 | 0.52 |
| Hepatitis C virus infection | 419 | 3.28 | 451 | 3.53 | 1.32 |
| Organ transplantation | 33 | 0.26 | 24 | 0.19 | −1.57 |
| Antidiabetic drugs and drugs that are commonly prescribed to diabetes patients or drugs that might affect exposure/outcome | |||||
| Insulin | 380 | 2.98 | 388 | 3.04 | 0.43 |
| Sulfonylureas | 8849 | 69.33 | 8894 | 69.69 | 0.58 |
| Metformin | 9381 | 73.50 | 9389 | 73.56 | 0.15 |
| Meglitinide | 905 | 7.09 | 879 | 6.89 | −1.00 |
| Acarbose | 1702 | 13.34 | 1742 | 13.65 | 0.89 |
| Angiotensin converting enzyme inhibitors/Angiotensin receptor blockers | 9404 | 73.68 | 9487 | 74.33 | 1.38 |
| Calcium channel blockers | 7273 | 56.99 | 7358 | 57.65 | 1.27 |
| Statins | 9457 | 74.10 | 9505 | 74.47 | 0.91 |
| Fibrates | 5736 | 44.94 | 5728 | 44.88 | −0.15 |
| Aspirin | 7594 | 59.50 | 7587 | 59.45 | −0.21 |
| Corticosteroids | 359 | 2.81 | 331 | 2.59 | −1.48 |
* Age and diabetes duration are shown as mean and standard deviation.
Table 2.
Incidence rates of inflammatory bowel disease and hazard ratios comparing pioglitazone exposed groups to the unexposed group.
Table 2.
Incidence rates of inflammatory bowel disease and hazard ratios comparing pioglitazone exposed groups to the unexposed group.
| Pioglitazone Use | Incident Case Number | Cases Followed | Person-Years | Incidence Rate (per 100,000 Person-Years) | Hazard Ratio | 95% Confidence Interval | p Value |
|---|---|---|---|---|---|---|---|
| Never users | 139 | 12,763 | 33,988.31 | 408.96 | 1.000 | ||
| Ever users | 113 | 12,763 | 34,154.60 | 330.85 | 0.809 | (0.631–1.037) | 0.0937 |
| Tertiles of cumulative duration of pioglitazone therapy (months) | |||||||
| Never users | 139 | 12,763 | 33,988.31 | 408.96 | 1.000 | ||
| <11.0 | 32 | 4147 | 10,833.86 | 295.37 | 0.727 | (0.495–1.068) | 0.1044 |
| 11.0–19.7 | 35 | 4282 | 11,466.87 | 305.23 | 0.745 | (0.514–1.079) | 0.1191 |
| >19.7 | 46 | 4334 | 11,853.86 | 388.06 | 0.942 | (0.675–1.315) | 0.7253 |
| Tertiles of cumulative dose of pioglitazone therapy (mg) | |||||||
| Never users | 139 | 12,763 | 33,988.31 | 408.96 | 1.000 | ||
| <7980 | 31 | 4155 | 10,897.90 | 284.46 | 0.700 | (0.474–1.033) | 0.0726 |
| 7980–14,940 | 37 | 4266 | 11,435.47 | 323.55 | 0.790 | (0.550–1.135) | 0.2018 |
| >14,940 | 45 | 4342 | 11,821.23 | 380.67 | 0.925 | (0.661–1.294) | 0.6478 |
Table 3.
Joint effects and interactions between pioglitazone and major risk factors of inflammatory bowel disease.
Table 3.
Joint effects and interactions between pioglitazone and major risk factors of inflammatory bowel disease.
| Risk Factor/Pioglitazone Use | Incident Case Number | Cases Followed | Person-Years | Incidence Rate (per 100,000 Person-Years) | Hazard Ratio | 95% Confidence Interval | p Value |
|---|---|---|---|---|---|---|---|
| Psoriasis (+)/Pioglitazone (−) | 3 | 419 | 1124.62 | 266.76 | 1.000 | ||
| Psoriasis (+)/Pioglitazone (+) | 6 | 374 | 994.22 | 603.49 | 2.329 | (0.581–9.332) | 0.2325 |
| Psoriasis (−)/Pioglitazone (−) | 136 | 12,344 | 32,863.69 | 413.83 | 1.602 | (0.509–5.043) | 0.4206 |
| Psoriasis (−)/Pioglitazone (+) | 107 | 12,389 | 33,160.38 | 322.67 | 1.250 | (0.396–3.947) | 0.7042 |
| P-interaction | 0.1286 | ||||||
| Arthropathies (+)/Pioglitazone (−) | 117 | 9628 | 25,741.21 | 454.52 | 1.000 | ||
| Arthropathies (+)/Pioglitazone (+) | 90 | 9685 | 25,978.83 | 346.44 | 0.763 | (0.580–1.005) | 0.0546 |
| Arthropathies (−)/Pioglitazone (−) | 22 | 3135 | 8247.10 | 266.76 | 0.687 | (0.427–1.107) | 0.1228 |
| Arthropathies (−)/Pioglitazone (+) | 23 | 3078 | 8175.77 | 281.32 | 0.731 | (0.457–1.169) | 0.1906 |
| P-interaction | 0.3149 | ||||||
| Dorsopathies (+)/Pioglitazone (−) | 113 | 9777 | 26,118.94 | 432.64 | 1.000 | ||
| Dorsopathies (+)/Pioglitazone (+) | 93 | 9792 | 26,258.73 | 354.17 | 0.820 | (0.623–1.079) | 0.1558 |
| Dorsopathies (−)/Pioglitazone (−) | 26 | 2986 | 7869.37 | 330.39 | 0.942 | (0.603–1.471) | 0.7920 |
| Dorsopathies (−)/Pioglitazone (+) | 20 | 2971 | 7895.87 | 253.30 | 0.726 | (0.444–1.188) | 0.2026 |
| P-interaction | 0.8522 | ||||||
| COPD/Tobacco abuse (+)/Pioglitazone (−) | 72 | 5960 | 15,908.15 | 452.60 | 1.000 | ||
| COPD/Tobacco abuse (+)/Pioglitazone (+) | 56 | 6038 | 16,163.84 | 346.45 | 0.760 | (0.536–1.079) | 0.1252 |
| COPD/Tobacco abuse (−)/Pioglitazone (−) | 67 | 6803 | 18,080.16 | 370.57 | 0.860 | (0.609–1.215) | 0.3932 |
| COPD/Tobacco abuse (−)/Pioglitazone (+) | 57 | 6725 | 17,990.76 | 316.83 | 0.744 | (0.520–1.066) | 0.1074 |
| P-interaction | 0.9709 | ||||||
| Any of the four (+)/Pioglitazone (−) | 130 | 11,333 | 30,243.27 | 429.85 | 1.000 | ||
| Any of the four (+)/Pioglitazone (+) | 104 | 11,370 | 30,483.71 | 341.17 | 0.797 | (0.615–1.031) | 0.0843 |
| All of the four (−)/Pioglitazone (−) | 9 | 1430 | 3745.04 | 240.32 | 0.660 | (0.332–1.310) | 0.2347 |
| All of the four (−)/Pioglitazone (+) | 9 | 1393 | 3670.88 | 245.17 | 0.668 | (0.336–1.327) | 0.2492 |
| P-interaction | 0.6240 |
COPD: chronic obstructive pulmonary disease.
Table 4.
Joint effect and interaction between metformin and pioglitazone on inflammatory bowel disease.
Table 4.
Joint effect and interaction between metformin and pioglitazone on inflammatory bowel disease.
| Metformin/Pioglitazone Use | Incident Case Number | Cases Followed | Person-Years | Incidence Rate (per 100,000 Person-Years) | Hazard Ratio | 95% Confidence Interval | p Value |
|---|---|---|---|---|---|---|---|
| Metformin (−)/Pioglitazone (−) | 33 | 3382 | 8911.51 | 370.31 | 1.000 | ||
| Metformin (−)/Pioglitazone (+) | 27 | 3374 | 8986.75 | 300.44 | 0.840 | (0.503–1.402) | 0.5043 |
| Metformin (+)/Pioglitazone (−) | 106 | 9381 | 25,076.80 | 422.70 | 1.186 | (0.793–1.771) | 0.4061 |
| Metformin (+)/Pioglitazone (+) | 86 | 9389 | 25,167.85 | 341.71 | 0.950 | (0.630–1.433) | 0.8074 |
| P-interaction | 0.6002 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Tseng, C.-H. Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus. Pharmaceuticals 2022, 15, 1538. https://doi.org/10.3390/ph15121538
AMA Style
Tseng C-H. Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus. Pharmaceuticals. 2022; 15(12):1538. https://doi.org/10.3390/ph15121538
Chicago/Turabian StyleTseng, Chin-Hsiao. 2022. "Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus" Pharmaceuticals 15, no. 12: 1538. https://doi.org/10.3390/ph15121538
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
